MyFinsight
Home
Blog
About
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$51M
Free Cash flow
-$119M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Proceeds from issuance of common...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Deferred revenue ((48) and (188)...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
-
17
33
214
Late-stage development programs
-
60
67
207
Early-stage development and preclinical programs
-
18
28
113
Compensation and personnel costs
-
70
58
187
Depreciation and amortization
-
2
3
7
Impairment of long-lived assets
-
-
0
0
Interest income, net
-
-6
-8
-25
Income tax expense
-
-
0
0
Other segment items
-
20
19
71
Partnership reimbursements
-
-19
-28
-99
Net loss
-91
-128
-106
-135
Stock-based compensation expense
15
19
15
14
Depreciation and amortization
3
2
3
2
Noncash lease expense
2
2
2
2
Impairment on right-of use assets
-
-
0
0
Amortization of discounts on marketable securities
2
3
3
3
Other items, net
1
1
-1
2
Receivable from collaboration partners ( and 2 from a related party)
3
-8
0
-4
Other assets
0
3
0
-6
Accounts payable ((12) and 13 to a related party)
-5
-3
0
13
Deferred revenue ((48) and (188) to a related party)
-37
-17
-26
-26
Other liabilities
-2
-16
-4
24
Net cash used in operating activities
-119
-138
-120
-97
Purchases of marketable securities
182
150
397
165
Proceeds from maturities of marketable securities
225
257
215
243
Proceeds from sales of marketable securities
9
7
1
1
Purchases of property and equipment
0
0
1
0
Net cash provided by investing activities
52
114
-182
79
Proceeds from issuance of common stock ( and 14 from a related party)
0
0
279
8
Proceeds from debt issuances, net
0
-
0
0
Proceeds from issuance of common stock pursuant to equity award plans
16
3
7
0
Payments of employee taxes related to net settlement of equity awards
-
-
0
0
Net cash provided by financing activities
16
3
286
8
Net increase (decrease) in cash, cash equivalents and restricted cash
-51
-21
-16
-10
Cash, cash equivalents and restricted cash at beginning of period
204
225
241
153
Cash, cash equivalents and restricted cash at end of period
153
204
225
241
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$225M
(-63.41%↓ Y/Y)
Proceeds from issuance of
common stock pursuant...
$16M
(433.33%↑ Y/Y)
Proceeds from sales of
marketable securities
$9M
(-86.96%↓ Y/Y)
Net cash provided by
investing activities
$52M
(-69.23%↓ Y/Y)
Net cash provided by
financing activities
$16M
(-91.75%↓ Y/Y)
Canceled cashflow
$182M
Net increase
(decrease) in cash, cash...
-$51M
(-152.04%↓ Y/Y)
Canceled cashflow
$68M
Stock-based compensation
expense
$15M
(-51.61%↓ Y/Y)
Depreciation and
amortization
$3M
(-40.00%↓ Y/Y)
Noncash lease expense
$2M
(-33.33%↓ Y/Y)
Other items, net
$1M
Purchases of marketable
securities
$182M
(-64.59%↓ Y/Y)
Net cash used in
operating activities
-$119M
(55.09%↑ Y/Y)
Canceled cashflow
$21M
Net loss
-$91M
(18.75%↑ Y/Y)
Deferred revenue ((48)
and (188) to a...
-$37M
(80.32%↑ Y/Y)
Accounts payable ((12)
and 13 to a related...
-$5M
(-145.45%↓ Y/Y)
Receivable from
collaboration partners ( and 2...
$3M
(160.00%↑ Y/Y)
Other liabilities
-$2M
(83.33%↑ Y/Y)
Amortization of discounts on
marketable securities
$2M
(-71.43%↓ Y/Y)
Buy us a coffee